Emergent BioSolutions Inc. EBS US Equity
Emergent BioSolutions Inc. (NYSE: EBS), an SEC filer in Pharmaceutical Preparations, closed at $5.91, -0.5%, on 2026-08-28, with a market cap of $305M as of 2026-08-27, a trailing P/E of 6.4, a return on equity of 10.5%, a net margin of 7.1% and 3-year sales growth of -12.7%. Institutional ownership, earnings history, filed financials and clinical trials are on the tabs below.